ABSTRACT
The past year has been one of great change and achievement for the Canadian stem cell community.
Subject(s)
Government Agencies/organization & administration , Stem Cell Research , Academies and Institutes/economics , Academies and Institutes/organization & administration , Canada , Drug Industry/economics , Drug Industry/organization & administration , Drug Industry/trends , Government Agencies/economics , Humans , Stem Cell Research/economics , Therapies, Investigational/methods , Therapies, Investigational/trendsABSTRACT
The International Consortium of Stem Cell Networks' (ICSCN) Workshop Towards Clinical Trials Using Stem Cells for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) was held on 24-25 January 2011. Twenty scientific talks addressed aspects of cell derivation and characterization; preclinical research and phased clinical trials involving stem cells; latest developments in induced pluripotent (iPS) cell technology; industry involvement and investment. Three moderated panel discussions focused on unregulated ALS/MND treatments, and the state of the art and barriers to future progress in using stem cells for ALS/MND. This review highlights the major insights that emanated from the workshop around the lessons learned and barriers to progress for using stem cells for understanding disease mechanism, drug discovery, and as therapy for ALS/MND. The full meeting report is only available in the online version of the journal. Please find this material with the following direct link to the article: http://www.informahealthcare.com/als/doi/10.3109/17482968.2011.590992 .
Subject(s)
Amyotrophic Lateral Sclerosis/surgery , Clinical Trials as Topic/trends , Stem Cell Transplantation/trends , Amyotrophic Lateral Sclerosis/pathology , Clinical Trials as Topic/methods , Education/trends , Humans , Internationality , Motor Neuron Disease/pathology , Motor Neuron Disease/surgery , Stem Cell Transplantation/methods , Stem Cells/cytologyABSTRACT
In 2001, the Stem Cell Network was the first of its kind, a bold initiative to forge and nurture pan-Canadian collaborations involving researchers, engineers, clinicians and private and public sector partners. Canada's broad and deep pool of stem cell talent proved to be a fertile ground for such an initiative, giving rise to a strong, thriving network that, 7 years later, can list innovative cell expansion and screening technologies, early-phase clinical trials for stroke, pulmonary hypertension, muscular dystrophy and cornea replacement, and leading discourse on ethical, legal and social issues among its accomplishments. As it moves into its second and final phase of funding, the Stem Cell Network continues to push boundaries and has set its sights on overcoming the obstacles that impede the transfer of research findings to clinical applications, commercial products and public policy.
Subject(s)
Biomedical Research/ethics , Commerce/ethics , Ethics, Medical , Regenerative Medicine/ethics , Stem Cells/cytology , Biotechnology , Canada , Clinical Trials as Topic , Humans , Ownership/legislation & jurisprudence , Patents as Topic/ethics , Policy Making , Regenerative Medicine/trends , Tissue Engineering/methodsABSTRACT
This article is a consensus statement by an international interdisciplinary group of academic experts and Canadian policy-makers on emerging ethical, legal and social issues in human embryonic stem cells (hESC) research in Canada. The process of researching consensus included consultations with key stakeholders in hESC research (regulations, stem cell researchers, and research ethics experts), preparation and distribution of background papers, and an international workshop held in Montreal in February 2007 to discuss the papers and debate recommendations. The recommendations provided in the consensus statement focus on issues of immediate relevance to Canadian policy-makers, including informed consent to hESC research, the use of fresh embryos in research, management of conflicts of interest, and the relevance of public opinion research to policy-making.
